Advances in Formulation and Delivery Will Help Pharmaceutical Firms Modify Proven Drugs by Targeting Molecules Now Off-Patent, Besides Developing Fifth-Generation Drugs Designed to Activate Stem Cells to Fight Diseases Such as Cancer, Lux Research Says
• Three clinical trials started at the Medical University of Vienna • Commissioned by multinational pharmaceutical firms
